Roivant Sciences Ltd. (NASDAQ:ROIV) Stock Has Consensus Price Target of $46.55 According to Brokerages

Key Points

• Analyst sentiment is moderately bullish: Fourteen brokerages rate Roivant Sciences “Moderate Buy,” with ten buys, one strong buy, two holds and one sell. The average 12-month price target is $46.55, versus a reported share price of $36.91.
• Roivant reported quarterly EPS of -$0.26, beating the consensus estimate of -$0.30, but revenue of $1.44 million fell short of the $2.06 million estimate. Analysts expect a full-year loss of approximately $2.00 per share.
• Insiders have been selling shares: insiders sold 1.82 million shares worth about $66.2 million over the prior 90 days, while institutional investors own 64.76% of the company.

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fourteen brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $46.55.

A number of research firms have recently weighed in on ROIV. TD Cowen reaffirmed a "buy" rating on shares of Roivant Sciences in a research note on Wednesday, October 21st. Wolfe Research cut Roivant Sciences from an "outperform" rating to a "peer perform" rating in a report on Monday, October 12th. HC Wainwright boosted their price target on Roivant Sciences from $41.00 to $47.00 and gave the stock a "buy" rating in a report on Tuesday, September 8th. Stifel Nicolaus assumed coverage on Roivant Sciences in a research note on Wednesday, September 16th. They issued a "buy" rating and a $51.00 price target for the company. Finally, Sanford C. Bernstein raised shares of Roivant Sciences to a "strong-buy" rating in a report on Wednesday, July 29th.

Roivant Sciences Stock Down 1.6%

NASDAQ ROIV opened at $36.91 on Friday. The stock's 50-day moving average price is $36.65 and its 200-day moving average price is $31.46. Roivant Sciences has a 52 week low of $19.30 and a 52 week high of $42.50. The company has a market capitalization of $26.66 billion, a P/E ratio of -69.64 and a beta of 1.10.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. The company had revenue of $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. Research analysts anticipate that Roivant Sciences will post -2.00 EPS for the current year.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, Director Melissa Epperly sold 17,750 shares of the business's stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $36.10, for a total transaction of $640,775.00. Following the completion of the transaction, the director owned 14,954 shares in the company, valued at $539,839.40. The trade was a 54.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mayukh Sukhatme sold 284,707 shares of the company's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75. Following the transaction, the insider directly owned 18,630,739 shares in the company, valued at approximately $675,364,288.75. This represents a 1.51% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 1,822,688 shares of company stock valued at $66,176,636. 8.80% of the stock is owned by corporate insiders.

Institutional Trading of Roivant Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of ROIV. Wellington Management Group LLP increased its stake in shares of Roivant Sciences by 179.0% during the 2nd quarter. Wellington Management Group LLP now owns 2,687,870 shares of the company's stock worth $95,124,000 after purchasing an additional 1,724,588 shares in the last quarter. Maverick Capital Ltd. purchased a new position in shares of Roivant Sciences during the 1st quarter worth about $45,066,000. Assenagon Asset Management S.A. boosted its holdings in shares of Roivant Sciences by 18.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company's stock valued at $295,965,000 after purchasing an additional 1,286,464 shares during the last quarter. Affinity Asset Advisors LLC increased its stake in Roivant Sciences by 64.7% during the first quarter. Affinity Asset Advisors LLC now owns 2,800,000 shares of the company's stock worth $77,560,000 after acquiring an additional 1,100,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. acquired a new stake in Roivant Sciences during the 3rd quarter worth approximately $35,624,000. Institutional investors own 64.76% of the company's stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd. NASDAQ: ROIV is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant's research and development activities have included immunology, dermatology, women's health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.